CN1027225C - 新的含降血钙素组合物及其制法 - Google Patents

新的含降血钙素组合物及其制法 Download PDF

Info

Publication number: CN1027225C
Authority: CN; China
Prior art keywords: calcitonin; class; glycyrrhetate; compositions; anguilla japonica
Prior art date: 1987-11-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CN88107895A

Other languages

English (en)

Chinese (zh)

Other versions

CN1033568A (zh

Inventor

瓦莱里奥·阿利韦蒂

卢恰诺·多里戈蒂

泰奥多罗·福尼奥

马利奥·平扎

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

If SpA

Original Assignee

If SpA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-11-13

Filing date

1988-11-12

Publication date

1995-01-04

1988-11-12 Application filed by If SpA filed Critical If SpA

1989-07-05 Publication of CN1033568A publication Critical patent/CN1033568A/zh

1995-01-04 Application granted granted Critical

1995-01-04 Publication of CN1027225C publication Critical patent/CN1027225C/zh

2003-11-12 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 86
229960004015 calcitonin Drugs 0.000 title claims abstract description 49
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title claims abstract description 48
102000055006 Calcitonin Human genes 0.000 title claims abstract description 47
108060001064 Calcitonin Proteins 0.000 title claims abstract description 47
238000002360 preparation method Methods 0.000 title claims description 29
LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 75
238000000034 method Methods 0.000 claims abstract description 27
238000010521 absorption reaction Methods 0.000 claims abstract description 17
210000004877 mucosa Anatomy 0.000 claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
239000003937 drug carrier Substances 0.000 claims abstract description 3
101000741442 Anguilla japonica Calcitonin Proteins 0.000 claims description 58
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 33
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
239000000546 pharmaceutical excipient Substances 0.000 claims description 12
230000002421 anti-septic effect Effects 0.000 claims description 6
210000002850 nasal mucosa Anatomy 0.000 claims description 5
238000001816 cooling Methods 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
239000007921 spray Substances 0.000 claims description 4
230000005540 biological transmission Effects 0.000 claims description 2
230000000680 avirulence Effects 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract description 4
VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 abstract description 3
239000003623 enhancer Substances 0.000 abstract description 3
LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 abstract description 3
229960004949 glycyrrhizic acid Drugs 0.000 abstract description 3
UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 abstract description 3
239000001685 glycyrrhizic acid Substances 0.000 abstract description 3
235000019410 glycyrrhizin Nutrition 0.000 abstract description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 69
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 66
238000009472 formulation Methods 0.000 description 31
239000000843 powder Substances 0.000 description 29
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 24
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 24
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 24
229960002216 methylparaben Drugs 0.000 description 24
239000012153 distilled water Substances 0.000 description 23
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 23
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 23
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 23
150000004683 dihydrates Chemical class 0.000 description 22
239000001509 sodium citrate Substances 0.000 description 22
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 22
235000002639 sodium chloride Nutrition 0.000 description 20
239000000243 solution Substances 0.000 description 17
239000011780 sodium chloride Substances 0.000 description 16
108090000765 processed proteins & peptides Proteins 0.000 description 15
239000000499 gel Substances 0.000 description 11
230000028016 temperature homeostasis Effects 0.000 description 11
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
239000008101 lactose Substances 0.000 description 10
239000003826 tablet Substances 0.000 description 10
210000002966 serum Anatomy 0.000 description 9
238000012360 testing method Methods 0.000 description 9
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
239000000443 aerosol Substances 0.000 description 8
239000011575 calcium Substances 0.000 description 8
229910052791 calcium Inorganic materials 0.000 description 8
239000003814 drug Substances 0.000 description 8
239000008187 granular material Substances 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000002904 solvent Substances 0.000 description 6
241000972773 Aulopiformes Species 0.000 description 5
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
229960000686 benzalkonium chloride Drugs 0.000 description 5
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 5
239000000872 buffer Substances 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
229940079593 drug Drugs 0.000 description 5
230000007774 longterm Effects 0.000 description 5
210000001331 nose Anatomy 0.000 description 5
235000019515 salmon Nutrition 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
238000001291 vacuum drying Methods 0.000 description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
239000002674 ointment Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
-1 pyroglutamic acid ester Chemical class 0.000 description 4
229910001220 stainless steel Inorganic materials 0.000 description 4
239000010935 stainless steel Substances 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
241000252087 Anguilla japonica Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
208000001132 Osteoporosis Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
210000003467 cheek Anatomy 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
239000006196 drop Substances 0.000 description 3
229960003720 enoxolone Drugs 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000000451 tissue damage Effects 0.000 description 3
231100000827 tissue damage Toxicity 0.000 description 3
238000005303 weighing Methods 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
KSIYPKPZIBBUFR-LJNLPFSOSA-N CSCC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O Chemical compound CSCC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O KSIYPKPZIBBUFR-LJNLPFSOSA-N 0.000 description 2
208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
229920003137 Eudragit® S polymer Polymers 0.000 description 2
101000741447 Gallus gallus Calcitonin Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
101000910302 Sus scrofa Calcitonin Proteins 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000001361 adipic acid Substances 0.000 description 2
235000011037 adipic acid Nutrition 0.000 description 2
239000003513 alkali Substances 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000000470 constituent Substances 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000006749 inflammatory damage Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
239000003380 propellant Substances 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000006190 sub-lingual tablet Substances 0.000 description 2
229940098466 sublingual tablet Drugs 0.000 description 2
239000000126 substance Substances 0.000 description 2
YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 2
229950004616 tribromoethanol Drugs 0.000 description 2
210000001215 vagina Anatomy 0.000 description 2
239000006216 vaginal suppository Substances 0.000 description 2
229940120293 vaginal suppository Drugs 0.000 description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241001125671 Eretmochelys imbricata Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
241000287826 Gallus Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
241000447437 Gerreidae Species 0.000 description 1
240000004670 Glycyrrhiza echinata Species 0.000 description 1
235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
HZYCAKGEXXKCDM-UHFFFAOYSA-N Methyl 2-(methylthio)acetate Chemical compound COC(=O)CSC HZYCAKGEXXKCDM-UHFFFAOYSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
241001597008 Nomeidae Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
241000473945 Theria <moth genus> Species 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001323 aldoses Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
229940043377 alpha-cyclodextrin Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
230000003260 anti-sepsis Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960001716 benzalkonium Drugs 0.000 description 1
CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000005660 chlorination reaction Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229950003988 decil Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
235000014654 dry sauces/powder mixes Nutrition 0.000 description 1
108700032313 elcatonin Proteins 0.000 description 1
229960000756 elcatonin Drugs 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
229940070818 glycyrrhizate Drugs 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
229940010454 licorice Drugs 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000003595 mist Substances 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
229940096978 oral tablet Drugs 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
238000005070 sampling Methods 0.000 description 1
210000003752 saphenous vein Anatomy 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229940087562 sodium acetate trihydrate Drugs 0.000 description 1
MOCOXAJEZKHXSF-IHMBCTQLSA-M sodium;(2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound [Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MOCOXAJEZKHXSF-IHMBCTQLSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000000003 vaginal tablet Substances 0.000 description 1
229940044977 vaginal tablet Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

CN88107895A 1987-11-13 1988-11-12 新的含降血钙素组合物及其制法 Expired - Fee Related CN1027225C (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT22647A/87		1987-11-13
IT22647/87A IT1223132B (it)	1987-11-13	1987-11-13	Composizione farmaceutica per somministrazione nasale

Publications (2)

Publication Number	Publication Date
CN1033568A CN1033568A (zh)	1989-07-05
CN1027225C true CN1027225C (zh)	1995-01-04

Family

ID=11198823

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN88107895A Expired - Fee Related CN1027225C (zh)	1987-11-13	1988-11-12	新的含降血钙素组合物及其制法

Country Status (11)

Country	Link
CN (1)	CN1027225C (fr)
BE (1)	BE1002333A3 (fr)
CA (1)	CA1329764C (fr)
FR (1)	FR2623090B1 (fr)
IL (1)	IL88316A (fr)
IT (1)	IT1223132B (fr)
MY (1)	MY104345A (fr)
NZ (1)	NZ226812A (fr)
PT (1)	PT88978B (fr)
ZA (1)	ZA888391B (fr)
ZW (1)	ZW14688A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT8920486A0 (it) *	1989-05-12	1989-05-12	Isf Spa	Composizioni farmaceutiche.
DE69001991T2 (de) *	1989-11-16	1993-09-23	Phidea Spa	Fluessige arzneimittel zur nasalen anwendung, die ein polypeptid als wirksubstanz enthalten.
IT1238072B (it) *	1990-01-19	1993-07-03	Sclavo Spa	Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
IT1248725B (it) *	1990-06-12	1995-01-26	Sclavo Spa	Composizione farmaceutica in polvere per somministrazione per via nasale contenente essenzialmente calcitonina ed un eccipiente idrosolubile
CN101721376B (zh) *	2009-12-30	2011-06-01	上海交通大学	降钙素缓释微球组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5927978A (ja) *	1982-08-09	1984-02-14	Terumo Corp	インドメタシン入り粘着テ−プ
JPS61267528A (ja) *	1984-11-26	1986-11-27	Yamanouchi Pharmaceut Co Ltd	吸収促進剤を含有するカルシトニン経鼻剤
CA1335076C (fr) *	1987-04-01	1995-04-04	Hanna R. Kowarski	Composition pharmaceutique et mode d'administration par voie intranasale

1987
- 1987-11-13 IT IT22647/87A patent/IT1223132B/it active Protection Beyond IP Right Term
1988
- 1988-10-31 MY MYPI88001240A patent/MY104345A/en unknown
- 1988-11-02 NZ NZ226812A patent/NZ226812A/xx unknown
- 1988-11-02 CA CA000581928A patent/CA1329764C/fr not_active Expired - Fee Related
- 1988-11-04 ZW ZW146/88A patent/ZW14688A1/xx unknown
- 1988-11-07 IL IL88316A patent/IL88316A/xx not_active IP Right Cessation
- 1988-11-08 FR FR888814576A patent/FR2623090B1/fr not_active Expired - Fee Related
- 1988-11-09 ZA ZA888391A patent/ZA888391B/xx unknown
- 1988-11-10 PT PT88978A patent/PT88978B/pt not_active IP Right Cessation
- 1988-11-10 BE BE8801287A patent/BE1002333A3/fr not_active IP Right Cessation
- 1988-11-12 CN CN88107895A patent/CN1027225C/zh not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IT8722647A0 (it)	1987-11-13
CA1329764C (fr)	1994-05-24
ZA888391B (en)	1989-08-30
PT88978B (pt)	1993-04-30
BE1002333A3 (fr)	1990-12-18
FR2623090B1 (fr)	1994-09-09
ZW14688A1 (en)	1989-08-02
PT88978A (pt)	1988-12-01
IT1223132B (it)	1990-09-12
IL88316A (en)	1993-04-04
MY104345A (en)	1994-03-31
NZ226812A (en)	1990-06-26
CN1033568A (zh)	1989-07-05
FR2623090A1 (fr)	1989-05-19

Legal Events

Date	Code	Title
1989-07-05	C06	Publication
1989-07-05	PB01	Publication
1991-01-09	C10	Entry into substantive examination
1991-01-09	SE01	Entry into force of request for substantive examination
1995-01-04	C14	Grant of patent or utility model
1995-01-04	GR01	Patent grant
2000-01-05	C19	Lapse of patent right due to non-payment of the annual fee
2000-01-05	CF01	Termination of patent right due to non-payment of annual fee

Publication	Publication Date	Title
CN1091314A (zh)	1994-08-31	含有降钙素的药物组合物
CN1180839C (zh)	2004-12-22	用于粘膜给药的含有聚合物药物的粉末制剂
CN1089583C (zh)	2002-08-28	霉酚酸2－(4－吗啉代)乙酯高剂量口服悬浮剂
CN1635900A (zh)	2005-07-06	Glp－1和基础胰岛素的预混合物
CN1703424A (zh)	2005-11-30	Glp－1衍生物及其经粘膜吸收的制剂
CN1406124A (zh)	2003-03-26	鼻给药的环肽组合物
CN1622822A (zh)	2005-06-01	含有生长素释放肽的药物组合物
CN1635832A (zh)	2005-07-06	施用glp－1分子的方法
CN1195776C (zh)	2005-04-06	肥胖症的治疗
CN101066276A (zh)	2007-11-07	用于治疗全身性炎症和炎性肝炎的嘧啶核苷酸前体
HK1046854A1 (en)	2003-01-30	Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes
CN1136852C (zh)	2004-02-04	头孢克罗的制药用配方
CN1037272A (zh)	1989-11-22	促旋酶抑制剂的肌内注射剂
CN1027225C (zh)	1995-01-04	新的含降血钙素组合物及其制法
CN1921859A (zh)	2007-02-28	用于治疗骨疾病的吲哚衍生物
CN1720061A (zh)	2006-01-11	结合p2y2或p2y1受体的化合物
CN1182453A (zh)	1998-05-20	Mpl配体类似物
CN1066781A (zh)	1992-12-09	含有碳酸酐酶抑制剂和β-肾上腺素能拮抗物的眼用组合物
CN1814601A (zh)	2006-08-09	具有免疫抑制作用的青蒿素衍生物及药物组合物
CN1313491C (zh)	2007-05-02	猫ω干扰素及其编码基因与应用
CN1257187C (zh)	2006-05-24	钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
CN1038838A (zh)	1990-01-17	聚醚抗菌素
CN1416817A (zh)	2003-05-14	灯盏花素分散片及其制备方法
CN1513448A (zh)	2004-07-21	藤黄酸及藤黄酸复合物的药物组合物制剂
CN101053566A (zh)	2007-10-17	乙酰半胱氨酸或其盐和抗感染药物的组合物